SUNSET
Financiado
Targeting cancer with multi-engineered selenium nanoparticles (SeNPs): Developme...
Targeting cancer with multi-engineered selenium nanoparticles (SeNPs): Development of a biocompatible nanocomposite for targeted gene therapy in BRAF-mutated resistant melanoma.
Nanotechnology has grown at an exponential rate in the last decade, finding a large application in the biomedical field. Nanoparticles are emerging as effective drug delivery tools, since they overcome most limitations of free the...
Nanotechnology has grown at an exponential rate in the last decade, finding a large application in the biomedical field. Nanoparticles are emerging as effective drug delivery tools, since they overcome most limitations of free therapeutics - while offering a series of physical/chemical advantages. Among engineered nanomaterials, selenium nanoparticles (SeNPs) have shown a growing potential as a therapeutic platform since they offer both the properties of selenium (Se) and the ones of a nanoscale system. SUNSET project aims is to design and develop a hydrogel-based nanocomposite containing multi-functionalised SeNPs, to use as an effective nanoplatform for cancer gene therapy. The designed system will be evaluated in resistant melanoma, specifically BRAF mutated lesions, which represent 66% of the cancer cases and are those that show resistance to currently available therapies, causing most cancer deaths. Here, the synthesis of SeNPs is followed by surface functionalisation with a specific small interfering RNA (siRNA) and their embedding in the polymeric phase. All the materials will be synthesised through green chemistry routes, to guarantee a low environmental impact of the procedure and its scalability and reproducibility. The anticancer activity of the nanocomposite will be evaluated both in vitro and in vivo. Overall, the combination of RNAi technology, nanomedicine and biocompatible materials – selenium and natural hydrogels – will be useful to gain a more efficient therapy, overcoming the main current challenges in the care of resistant melanomas. Moreover, the simplicity of the fabrication and the possibility to scale up the procedure, make the proposed system possibly attractive for clinical applications, promoting European Scientific Excellence. Lastly, I will have the possibility to start new cross-disciplinary collaborations that will pave the way for my future research career.
ver más
Duración del proyecto: 26 meses
Fecha Inicio: 2023-03-15
Fecha Fin: 2025-05-31
Fecha Fin: 2025-05-31
Línea de financiación: concedida
El organismo HORIZON EUROPE notifico la concesión del proyecto el día 2023-03-15
Línea de financiación objetivo
El proyecto se financió a través de la siguiente ayuda:
HORIZON-MSCA-2022-PF-01-01:
MSCA Postdoctoral Fellowships 2022
Cerrada
hace 2 años
Presupuesto
El presupuesto total del proyecto asciende a
188K€
Líder del proyecto
ACADEMISCH ZIEKENHUIS GRONINGEN
No se ha especificado una descripción o un objeto social para esta compañía.
Perfil tecnológico
TRL
4-5
Perfil tecnológico
TRL
4-5